my thoughts remain that Pluristem did the sale to put the proceeds to work to advance the expanded CLI program... and... did so without doing another offering...
It was Einstein who said “Make things as simple as possible, but no simpler.” Your take has the advantage that it's the most likely reason for the sale. It's simple, obvious, rational, ... a small biotech needs funds and here is a clean way to get it!
The company now has an extra six million bucks (that's a GOOD thing!!!), and they just received a very significant vote of confidence from the FDA for the CLI program.
All in all, it's a good time to be a PSTI long, and to continue to accumulate.